



SUMMARY OF ASSAY PROCEDURE




Figure S1. Summary of the ELISA protocol followed as described by the manufacturer. Kits used are the humanized IgG monoclonal antibody against SARS-CoV-2 Nucleocapsid Protein ELISA kit (SKU 41A227, Immunodiagnostics Ltd., Hong Kong) and humanized anti-S1RBD IgG monoclonal antibody ELISA kit (SKU 41A236, Immunodiagnostics Ltd., Hong Kong).




Figure S2. Change in antibody level across time. **(A)** Distribution of anti-NP IgG positivity index against time calculated (in days) as the time elapsed between the date of infection and the date of blood sampling **(B)** Distribution of anti-S1RBD IgG positivity index against time calculated (in days) as the time elapsed between the date of infection and the date of blood sampling. The space between vertical red dotted line represent 1-month intervals. A best fit line is constructed based on a linear regression model (dotted line in **(A)**, and solid line in **(B)**). The decrease in **(A)** is shown to be significant ($p = 0.02$) while the decrease in **(b)** is not significant ($p = 0.40$).